Donepezil Effect on Visual Attention and Training
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01738295|
Recruitment Status : Completed
First Posted : November 30, 2012
Last Update Posted : June 5, 2017
The present proposal investigates the role of the cholinergic system (the neurotransmitter acetylcholine) in improving vision and visual attention. Vision results from a complex processing of particular stimuli of the visual field. Attention enhances and prolongs the neural representations of visual input in the visual cortex. It has recently been shown that attention in the visual cortex depends on cholinergic mechanisms. The action of acetylcholine in the visual cortex consists in enhancement of the responsiveness to thalamocortical inputs, depression of local neuronal connections or extrastriate feedback projections and induction of gamma synchronisation. The investigators hypothesize that these effects are associated with long-term changes in functional connectivity in the visual cortex, visual attention and visual learning (improvement of the visual capacities).
In the present proposal, the investigators will test whether the administration of donepezil (Aricept, 5mg), a drug that increases the level of acetylcholine in the brain, will enhances the perceptual-cognitive abilities of young adult subjects. Perceptual-cognitive performance will be assessed in a multiple object tracking (MOT) task in a 3D automatic virtual environment. MOT is a task where observers are asked to maintain attentional focus on a limited number of preselected subgroup of elements in a dynamic scene. Multifocal attentional mechanisms are necessary to process the information. The task will be tested five time at one week interval to test whether donepezil and training improved the task performance of the subject, i.e. lead to perceptual learning. This study could help establish an intervention procedure to improve visual performance of subjects that need it.
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: Donepezil administration Drug: Placebo administration||Not Applicable|
Stages of a given perceptual-cognitive task (from Faubert and Sidebottom, Journal of Clinical Sport Psychology, 2012, 6, 85-102):
- a predetermined number of spheres (typically eight) are presented in a 3D dimensional virtual volumetric cube space. The spheres are typically all identical.
- a subset of spheres (typically four) is indexed via highlighting for a brief period of 1 s.
- the spheres return to their original color and start moving within the restricted 3D virtual space. During this movement, the spheres can collide and consequently suddenly change direction, and they can cross over others, thus occluding their view.
- the spheres stop moving after a predetermined time, and the observer has to identify the spheres that were initially indexed with halos. The subject is then given feedback on the response by having the spheres identified by revealing the appropriate indexed stimuli.
The main task starts at a given speed, and if all four spheres are not correctly identified, the next trial will be slower. If the four spheres are correctly identified, then the next trial will be faster. Trials are repeated like this following a staircase procedure, and ultimately, a speed threshold is established.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Donepezil Effect on Visual Attention and Perceptual Training in Healthy Young Adults|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||August 2014|
|Actual Study Completion Date :||August 2015|
Active Comparator: Donepezil
Donepezil administration. In this group Donepezil (Aricept pill, 5 mg) will be orally administrated 3h before each experiment (1 week intervals)
Drug: Donepezil administration
Other Name: Aricept, Pfizer
Placebo Comparator: Lactose pill
Placebo administration. In this group, placebo (lactose pill) will be orally administrated 3h before each experiments (1 week intervals)
Drug: Placebo administration
Other Name: Lactose pill
- Measure of the speed threshold, baseline [ Time Frame: week 0 ]The speed of the moving spheres is increased across trials until the subject is not able anymore to track and identify the indexed spheres (speed threshold). In this baseline task, the subject will not take Donepezil or placebo
- Change from baseline of the speed threshold at 1 week [ Time Frame: week 1 ]The speed of the moving spheres is increased across trials. The maximal speed for which the subject is able to track and identify the indexed spheres is the speed threshold. At this time point, the effect of Donepezil (5 mg, single dose) or placebo administration on the perceptual-cognitive performance will be assessed.
- Change from baseline of the speed threshold at 2 weeks [ Time Frame: week 2 ]The speed of the moving spheres is increased across trials. The maximal speed for which the subject is able to track and identify the indexed spheres is the speed threshold. At this time point, the effect of Donepezil (5 mg, single dose) or placebo administration on the perceptual-cognitive performance will be assessed.
- Change from baseline of the speed threshold at 3 weeks [ Time Frame: week 3 ]The speed of the moving spheres is increased across trials. The maximal speed for which the subject is able to track and identify the indexed spheres is the speed threshold. At this time point, the effect of Donepezil (5 mg, single dose) or placebo administration on the perceptual-cognitive performance will be assessed.
- Change from baseline of the speed threshold at 4 weeks [ Time Frame: week 4 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01738295
|School of optometry / Université de Montréal|
|Montréal, Quebec, Canada, H3T 1P1|
|Study Director:||Elvire Vaucher, PhD||Université de Montréal|
|Study Director:||Jocelyn Faubert, PhD||Université de Montréal|
|Principal Investigator:||Isabelle Legault, PhD||Université de Montréal|
|Principal Investigator:||Mira Chamoun, MSc||Université de Montréal|